Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2020

Open Access 01-07-2020 | Breast Cancer | Case Report

Postoperative radiotherapy-induced leiomyosarcoma in breast cancer: a case report and literature review

Authors: Yong Liu, Jiaming Wang, Rong Su, Yi Tang, Xiaoli Liao

Published in: Breast Cancer | Issue 4/2020

Login to get access

Abstract

Radiation-induced sarcoma (RIS) is a late complication of breast cancer radiotherapy, with a very low incidence, long latent period and poor prognosis. Among them, leiomyosarcoma after radiation is an extremely rare radiation-associated sarcoma. In this study, we report a case of radiation-induced leiomyosarcoma 2 years after postoperative radiotherapy for breast cancer. After the diagnosis of leiomyosarcoma, the patient received radical resection of the left chest wall leiomyosarcoma. The patient showed no relapse or progression during the follow-up time of 1 year after operation. Rare occurrence of RIS induced by postoperative radiotherapy in breast cancer and limited experience concerning its diagnosis and treatment bring obstacle to both patients and doctors. Preoperative examinations must be carefully refined. With a perfect coordination between different disciplines, RIS induced by postoperative radiotherapy in breast cancer can be ideally treated with better prognosis.
Literature
1.
Taghian A, de Vathaire F, Terrier P, Le M, Auguier A, Mouriesse M, et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys. 1991;21:361–7.PubMed
2.
Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A. Radiation-induced sarcomas after radiotherapy for breast carcinoma. A large-scale single-institution review. Cancer. 2005;104(4):856–63.
3.
Virtanen A, Pukkala E, Auvinen A. Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients. Int J Cancer. 2006;118:1017–21.PubMed
4.
Cahan WG, Woodward HQ, Higinbotham NL, Stewart FW. Sarcoma in irradiated bone: report of 11 cases. Cancer. 1948;1:2–29.
5.
Arlen N, Higinbotham NL, Huvos AG. Radiation-induced sarcoma of the bone. Cancer. 1971;28:1087–99.PubMed
6.
Beck A. Long-term balanced fertilization increases the soil microbial functional diversity in a phosphorus-limited paddy soil. Molecular Ecology. 2015;69:623–5.
7.
Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231–7.PubMed
8.
Salminen SH, Sampo MM, Böhling TO, Tuomikoski L, et al. Radiation-associated sarcoma after breast cancer in a nationwide population: increasing risk of angiosarcoma. Cancer Med. 2018;7(9):4825–35.PubMedPubMedCentral
9.
Cha C, Antonescu CR, Quan ML, et al. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg. 2004;239(6):903–10.PubMedPubMedCentral
10.
Blanchard DK, Reynolds C, Grant CS, Farley D. On the history of a reoccurring concept: Phosphorus scarcity. Science of The Total Environment. 2014;490(4):356–8.PubMed
11.
Mark RJ, Poen J, Tran LM, et al. Postirradiation sarcomas: a single-institution study and review of the literature. Cancer. 201573(10):2653–62.PubMed
12.
Georgiannos SN, Sheaff M. Integration of P acquisition efficiency, P utilization efficiency and low grain P concentrations into P-efficient rice genotypes for specific target environments. Nutrient Cycling in Agroecosystems. 2016;56(2):129–34.PubMed
13.
Laskin WB, Silverman TA, Enzinger FM. Postradiation soft tissue sarcomas: an analysis of 53 cases. Cancer. 1988;62:2330–40.PubMed
14.
Wiklund TA, Blomqvist CP, Raty J, Elomaa I, Rissanen P, Miettinen M. Postirradiation sarcoma: analysis of a Nationwide Cancer Registry Material. Cancer. 1991;68:524–31.PubMed
15.
Kim JH, Chy FC, Woodward HQ, Huvos A. Radiation induced sarcomas of bone following therapeutic radiation. Int J Radiat Oncol Bid Phys. 1983;9:107–10.
16.
Rubino C, Shamsaldin A, Le MG, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat. 2005;89:277–88.PubMed
17.
Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci. 2001;114(Pt 20):3591–8.PubMed
18.
19.
De Smet S, Vandermeeren L, Christiaens MR, et al. Aboveground and belowground effects of single-tree removals in new zealand rain forest. Ecology. 2008;89(5):574–9.PubMed
20.
Erel E, Vlachou E, Athanasiadou M, et al. Management of radiation-induced sarcomas in a tertiary referral centre: a review of 25 cases. Breast. 2010;19(5):424–7.PubMed
21.
Gutman H, Pollock RE, Ross MI. Sarcoma of the breast: implications for extent of therapy. Surgery. 1994;116:505–9.PubMed
22.
Kirova Y, Vilcoq JR, Asselain B, Sastre-Garau X, Campana F, Dendale R. Radiation-induced sarcomas after breast cancer: experience of Institute Curie and review of literature. Cancer Radiother. 2006;10:83–90.PubMed
23.
Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens—a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Clin Oncol. 1999;17(1):150–7.
Metadata
Title
Postoperative radiotherapy-induced leiomyosarcoma in breast cancer: a case report and literature review
Authors
Yong Liu
Jiaming Wang
Rong Su
Yi Tang
Xiaoli Liao
Publication date
01-07-2020
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2020
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-020-01050-x

Other articles of this Issue 4/2020

Breast Cancer 4/2020 Go to the issue

Original Article

Fat necrosis in level I oncoplastic breast-conserving surgery focusing on a modified round block technique

Original Article

lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer

Original Article

Could ductoscopy alleviate the need of microdochectomy in pathological nipple discharge?

Correction

Correction to: Histological classification of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition)

Special Article

Annual report of the Japanese Breast Cancer Society registry for 2016

Original Article

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits